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I M M U N O L O G Y
Inhaled GM-CSF in neonatal mice provides durable 
protection against bacterial pneumonia
Elizabeth M. Todd, Rashmi Ramani, Taylor P. Szasz, S. Celeste Morley*
Pneumonia poses profound health threats to preterm infants. Alveolar macrophages (AMs) eliminate inhaled 
pathogens while maintaining surfactant homeostasis. As AM development only occurs perinatally, therapies that 
accelerate AM maturation in preterms may improve outcomes. We tested therapeutic rescue of AM development 
in mice lacking the actin-bundling protein L-plastin (LPL), which exhibit impaired AM development and increased 
susceptibility to pneumococcal lung infection. Airway administration of recombinant granulocyte-macrophage 
colony-stimulating factor (GM-CSF) to LPL−/− neonates augmented AM production. Airway administration 
distinguishes the delivery route from prior human infant trials. Adult LPL−/− animals that received neonatal 
GM-CSF were protected from experimental pneumococcal challenge. No detrimental effects on surfactant metabolism 
or alveolarization were observed. Airway recombinant GM-CSF administration thus shows therapeutic promise to 
accelerate neonatal pulmonary immunity, protecting against bacterial pneumonia.
INTRODUCTION
Pneumonia causes considerable morbidity and mortality in pre-
mature infants and neonates (1, 2), yet remarkably little is known 
about host susceptibility to, and the pathophysiology of, lower 
respiratory tract infections in this age group. In particular, the 
development of innate immunity in preterm infant lungs is poorly 
understood. Given that alveolar macrophages (AMs) have unique 
roles as first responders to pathogenic infection and in maintaining 
the anti-inflammatory, homeostatic environment of the lungs con-
ducive to appropriate lung development, understanding how the 
appearance of AMs is affected by preterm birth is essential to 
understanding how preterm infants may respond to pulmonary 
pathogen challenge (2–7).
A major paradigm shift occurred when Schulz et al. (8) demon-
strated that tissue-resident macrophages arise during embryogenesis 
from yolk sac precursors and are not continuously rederived from 
circulating peripheral blood monocytes. The recognition that each 
tissue-resident macrophage lineage derives along a unique pathway, 
following distinct development and tissue-specific cues and finishing 
with specialized phenotypic markers and functions, revolutionized 
basic immunologists’ understanding and appreciation for the complex 
nature of the tissue-resident phagocytic system (9–19). AMs epito-
mize the highly specialized nature of tissue-resident macrophages, 
as they express CD11c (not CD11b) and depend on the growth 
factor granulocyte-macrophage colony-stimulating factor (GM-CSF) 
and the transcription factor peroxisome proliferator–activated 
receptor . They also arise during a temporally limited phase of 
development, which in mice begins on embryonic day 16 and closes 
on postnatal day 7 (PND7). They arise from monocyte precursor 
cells that seed the lungs of mice during embryonic days 15 and 16, 
coincident with the saccular phase of lung development (20). These 
monocytes develop to the intermediary pre-AM in the days before 
birth and then advance to fully mature AMs in mice by PND7 (9). 
Pre-AMs and AMs are phenotypically distinguished by surface 
markers; pre-AMs express CD11c, while AMs express both CD11c 
and SiglecF. The pre-AM, as a developmental intermediary, can only 
be found in the lungs from late embryonic or early neonatal mice 
(not adult). AM development during the perinatal period is driven 
by a burst of GM-CSF production, which subsides after birth (14). 
After the first week of life, no new precursor cells are generated, and 
in the absence of overwhelming inflammation, AMs self-renew over 
the lifetime of the host (9, 21).
In addition to serving as sentinel cells, engulfing pathogens, and 
preventing subsequent lung infection (13, 22), AMs are functionally 
distinct from interstitial lung macrophages in that AMs are programmed 
to tilt toward an anti-inflammatory, prohealing phenotype. AMs 
thus protect and preserve the delicate alveolar structure from 
inflammatory insults. In human infants, AMs can arise post-natally 
in the first 2 days (3, 4, 6, 23, 24); therefore, we posit that the exogenous 
augmentation of AM development may represent a new avenue to 
protect preterm infants from pulmonary disease. In our mouse 
model featuring the partial disruption of AM development, mice 
were rendered susceptible to pneumococcal challenge (22, 25). 
Mice lacking the actin-bundling protein L-plastin (LPL−/− mice) 
and CD11c.Cre+-LPLfl/fl mice exhibited cell intrinsic defects in AM 
production secondary to the diminished migration of AM precursors 
to, and retention within, the alveoli. LPL−/− and CD11c.Cre+-LPLfl/fl 
mice also exhibited impaired pneumococcal clearance from the 
lungs following intratracheal challenge, associated with increased 
dissemination to the bloodstream and decreased survival (22, 25). 
Because GM-CSF signaling is independent of LPL (22), we considered 
these mice to represent an ideal model system to test the therapeutic 
potential of GM-CSF delivery to neonates. We now show that the 
intranasal administration of GM-CSF to neonatal mice in the first 
week of life enhances AM development. We note that the systemic 
administration of GM-CSF did not enhance AM maturation as did 
direct airway administration, and therefore, these effects would not 
have been apparent in prior clinical trials of GM-CSF in preterm 
infants (26). Most notably, the augmented population of AMs 
persists to adulthood, and animals treated in the neonatal period 
are protected as adults from mortality during pneumococcal lung 
infection.
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RESULTS
Neonatal administration of rGM-CSF enhances 
AM population in LPL−/− mice
We have previously shown that LPL−/− mice exhibit defective AM 
development due to the impaired migration of pre-AM precursors 
into the alveolar space (22). Impaired migration results in reduced 
numbers of mature AMs and subsequent susceptibility to pneumo-
coccal lung infection. Notably, AM precursors in LPL−/− mice retain 
responsiveness to the required growth factor GM-CSF (22). We 
undertook the present study to determine whether perinatal AM 
development could be augmented by the exogenous intranasal 
administration of GM-CSF and provide durable protection against 
pneumococcal lung infection.
To test whether the airway administration of GM-CSF would 
augment AM maturation during the normal physiological window 
of development, we intranasally administered recombinant GM-CSF 
(rGM-CSF) to wild-type (WT) and LPL−/− mouse pups or phosphate- 
buffered saline (PBS) to control mice on the day of birth (DOB), 
PND1, and PND2 (Fig. 1A). Mice were euthanized on PND3, and 
populations of fetal monocytes, pre-AMs, and AMs in whole-lung 
homogenates were determined by flow cytometry (Fig. 1B) (9). As 
previously observed (22), untreated LPL−/− pups showed no defi-
ciencies in fetal monocyte or pre-AM populations compared to WT 
pups but did exhibit a reduced percentage of mature AMs. The 
administration of rGM-CSF to LPL−/− pups increased the proportion 
of CD11c+ maturing cells (combined pre-AMs and AMs; Fig. 1C), 
while these proportions were unchanged by rGM-CSF administration 
to WT pups. Administering the same amount of rGM-CSF (20 ng) 
to LPL−/− pups via subcutaneous injection (systemic administration) 
on DOB, PND1, and PND2 did not enhance AM maturation, as 
assessed on PND6 (fig. S1).
To determine whether neonatal rGM-CSF administration elicited 
durable change in AM numbers, we analyzed the percentage and 
numbers of AMs recovered from adult (defined as ≥8 week old) 
animals that had received intranasally either PBS or rGM-CSF as 
neonatal pups. As previously observed (22), untreated adult LPL−/− 
mice exhibited reduced AMs compared with WT mice (Fig. 1, 
D and E). However, LPL−/− mice that had received rGM-CSF as pups 
harbored significantly higher numbers of AMs in bronchoalveolar 
lavage (BAL) fluid (Fig. 1E), while similarly treated WT mice 
demonstrated no alteration in AMs. Thus, exogenous rGM-CSF 
enhanced AM production under conditions where maturation was 
impaired but did not alter normal AM development.
GM-CSF has been considered pro-inflammatory in the lung (27), 
and excess inflammation has been associated with the disruption of 
alveolarization in neonatal mice (5). To test whether the exogenous 
administration of rGM-CSF to neonatal pups interfered with alveo-
larization in the developing lungs, histological sections of WT and 
LPL−/− pups (PND3) and adults that received either PBS or rGM-CSF 
were examined by a veterinary pathologist. No disruption of alveo-
larization was observed (fig. S2).
Neonatal rGM-CSF administration protected adult LPL−/− 
mice from infection
To determine whether enhanced neonatal AM development protected 
mice from subsequent infection, adult LPL−/− mice that received 
neonatal rGM-CSF were challenged intratracheally with pneumococcus 
(Fig. 2A). We selected the same inoculum used in our prior studies, 
in which about 10 to 20% of WT animals would be expected to 
succumb, while up to 70 to 80% of LPL−/− mice might succumb. 
This sizable differential in susceptibility would provide the optimal 
conditions for observing an effect of neonatal rGM-CSF therapy, if 
any (22, 25). As anticipated, untreated LPL−/− mice were more 
susceptible to pneumococcal pneumonia than were WT mice (Fig. 2B). 
However, adult LPL−/− mice that had received neonatal rGM-CSF 
therapy were significantly protected from mortality, while the already 
low mortality in infected WT mice was unaltered by neonatal rGM-CSF 
therapy (Fig. 2B). Quantitative blood cultures obtained 24 hours 
after pneumococcal inoculation revealed that untreated LPL−/− mice 
suffered from augmented dissemination (Fig. 2C), as reported 
previously (25) and aligned with their increased mortality. The 
neonatal rGM-CSF treatment of LPL−/− mice reduced pneumococcal 
bloodstream dissemination in infected adults to match that in WT 
animals, showing that the neonatal administration of inhaled rGM-CSF 
provided sustained rescue of pulmonary host defense. An analysis 
of peripheral blood 24 hours after infection revealed no significant 
difference in the percentages of circulating neutrophils or monocytes 
in infected WT or LPL−/− mice treated with neonatal PBS or rGM-
CSF. LPL−/− mice exhibit reduced B cell maturation (28), which was 
expectedly unchanged by neonatal rGM-CSF intranasal adminis-
tration (Fig. 2D). Thus, we did not find evidence that intranasal 
neonatal rGM-CSF treatment altered systemic host immune responses 
(Fig. 2D) while protecting against pulmonary infection (Fig. 2, B and C).
We also quantified AMs in the BAL of adult animals that survived 
2 weeks after intratracheal pneumococcal inoculation. AM numbers 
in control and rGM-CSF–treated WT animals were equivalent. 
Untreated LPL−/− mice again exhibited reduced AM numbers compared 
to WT animals, while rGM-CSF–treated LPL−/− mice harbored AM 
numbers equivalent to those of WT animals (Fig. 2E). We did not 
observe any changes in the proportions of other pulmonary innate 
immune cell types [dendritic cells (DCs), eosinophils, neutrophils, 
or monocytes] preceding infection (Fig. 2F). Protection from pneu-
mococcal infection thus correlated specifically with increased AM 
populations.
Neonatal rGM-CSF administration enhances 
AM and AM precursor proliferation
We next sought to define a mechanism by which exogenous rGM-CSF 
therapy enhanced AM neonatal development. We have previously 
shown that the migration of AM precursors into the alveoli is 
impaired in the absence of LPL. While it is not obvious how rGM-CSF 
could overcome this migration defect, we hypothesized that exogenous 
rGM-CSF could increase the proliferation of precursor cells that do 
successfully reach the alveoli in LPL−/− pups—in other words, acting 
on cells “already there.” Furthermore, the contribution of proliferation 
to the increase in lung-resident monocyte, pre-AM, and AM populations 
during neonatal development has not been previously assessed. We 
therefore quantified 5-bromo-2′-deoxyuridine (BrdU) incorporation 
into monocytes, pre-AMs, and AMs in PND3 pups treated intranasally 
with PBS or rGM-CSF (Fig. 3A). AMs and precursors were identified 
using surface expression of CD11b, F4/80, CD11c, SiglecF, and 
Ly6C as previously defined [Fig. 1B and (9)]. In untreated WT pups, 
we noted proliferation in all three subpopulations, with substantial 
BrdU incorporation into fetal monocytes and AMs; meanwhile, 
BrdU incorporation into all three cell types was diminished in 
LPL−/− pups (Fig. 3, A and B). Notably, neonatal rGM-CSF treatment 
significantly increased pre-AM proliferation by threefold in LPL−/− 
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Fig. 1. Administration of rGM-CSF increases AMs in LPL−/− mice. (A) rGM-CSF (20 ng) in 6 l of PBS was administered via intranasal (i.n.) instillation to neonatal pups on 
DOB, PND1, and PND2. Mice were evaluated at indicated times after rGM-CSF administration. (B) Representative flow cytometry of whole-lung homogenates from PND3 
WT and LPL−/− pups treated intranasally with PBS or rGM-CSF. (C) Quantification of the distribution of monocytes, pre-AMs, AMs, and total CD11c+ (maturing) cells in PND3 
WT and LPL−/− pups. (D) Representative flow cytometry from BAL fluid obtained from adult WT and LPL−/− mice that had received neonatal rGM-CSF therapy. (E) Percentage 
and number of AMs recovered from BAL fluid from adult WT and LPL−/− mice that had received neonatal rGM-CSF treatment. (C and E) n of each group is provided below 
x axes. Data were obtained from four independent cohorts of animals. P values are determined using the Mann-Whitney U test. Kruskal-Wallis test comparing four groups 
revealed P = 0.0014 for AM % (top) and P = 0.015 for AM numbers (bottom). The “n” of AM numbers (bottom) in some groups is lower than AM % (top) because cell 
numbers in one experiment were counted manually rather than by cytometer acquisition. Only cell counts obtained by the same method (cytometer acquisition) are included 
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mature AM numbers in LPL−/− mice is by enhancing the proliferation 
of precursors that do succeed in reaching the alveolar space. Intranasal 
rGM-CSF therapy had no effect on the proliferation of pre-AMs 
or AMs in WT mice, again indicating that rGM-CSF therapy exerts 
little, if any, effect on AM development that is proceeding normally 
(Fig. 3B).
Recently, the autocrine production of transforming growth 
factor– (TGF-) has been shown to be essential for AM development 
and maintenance (29). We had not previously evaluated whether 
TGF- production by AMs was altered by LPL deficiency. Furthermore, 
if TGF- were dependent on LPL for generation, then a second 
mechanism of AM rescue by rGM-CSF could be by augmenting 
TGF- production. Refuting this possibility, we found no difference 
in the whole-lung TGF- concentration in PND3 WT or LPL−/− 
pups that had received PBS or rGM-CSF (Fig. 3C).
Neonatal rGM-CSF improves surfactant homeostasis 
in LPL−/− mice
In addition to their critical role in host defense, AMs are essential to 
surfactant metabolism. Surfactant is produced by alveolar epithelial 
type II cells but taken up and catabolized in part by AMs, a process 
stimulated by GM-CSF. Animals deficient in GM-CSF or the GM-CSF 
receptor suffer from primary alveolar proteinosis, a progressive 
and ultimately fatal accumulation of surfactant protein in the alveoli 
(30–32). Although LPL−/− animals have not exhibited overt evidence 
of progressive lung disease (22, 25), we have not previously formally 
assessed surfactant protein in these mice. In addition, we wished to 
determine whether neonatal rGM-CSF treatment would alter surfactant 
catabolism in WT or LPL−/− mice. We therefore quantified surfactant 
protein D (SP-D) and SP-A in WT and LPL−/− mice that had received 
intranasally either PBS or rGM-CSF as pups (Fig. 4). In PND3 and 
adult LPL−/− mice, the amount of SP-D per milligram of lung tissue 
was increased in LPL−/− whole-lung homogenates compared to 
untreated WT mice (Fig. 4A). Neonatal rGM-CSF therapy in LPL−/− 
mice partially ameliorated the increase in SP-D by PND3 and 
normalized SP-D concentrations by adulthood while not altering SP-D 
levels in WT mice (Fig. 4A). SP-A concentrations were not altered 
in the lungs of adult untreated LPL−/− mice and were not affected by 
neonatal rGM-CSF therapy (Fig. 4B). An analysis of SP-D and SP-A 
protein amounts compared to total lung protein revealed similar 
trends (fig. S3). Therefore, neonatal rGM-CSF therapy did not alter 
surfactant metabolism in WT mice but ameliorated defects in 
LPL−/− mice associated with reduced AM production.
DISCUSSION
Here, we used a preclinical model of impaired AM development 
to show that GM-CSF, a readily available, U.S. Food and Drug 
Administration–approved therapy, can be administered safely to 
the airways of newborn mice to accelerate AM maturation (Fig. 1) 
and protect otherwise susceptible animals from bacterial pneumonia 
(Fig. 2). One mechanism by which rGM-CSF rescues AM development 
in LPL−/− mice is by significantly increasing pre-AM proliferation 
(Fig. 3B) without affecting levels of TGF- or disrupting alveo-
larization or normal surfactant homeostasis (Fig. 4 and fig. S2). We 
propose that the translation of neonatal GM-CSF therapy to human 
infants could have a direct impact on improving outcomes of respiratory 
disease in preterm neonates, a benefit that would not have been 
apparent in prior studies that either subcutaneously or intravenously 
Fig. 2. Adult LPL−/− mice that received neonatal rGM-CSF therapy are protected 
from pneumococcal infection. (A) Experimental design: Neonatal WT and LPL−/− 
pups were intranasally given 20 ng of rGM-CSF or PBS (control) on DOB, PND1, and 
PND2. After reaching adulthood, mice were challenged intratracheally (i.t.) with 
pneumococcus. (B) Adult WT (gray) or LPL−/− (black) mice that had received neonatal 
rGM-CSF therapy (open symbols) or PBS (control; closed symbols) were infected 
intratracheally with pneumococcus and monitored for survival. Survival curves show 
data combined from three independent experiments (WT + PBS, n = 19; WT + rGM-CSF, 
n = 7; LPL−/− + PBS, n = 11; LPL−/− + rGM-CSF, n = 16) and were compared using 
Mantel-Cox log-rank test. (C) Quantitative blood culture obtained from adult mice 
24 hours after intratracheal instillation of pneumococci. Comparison of all groups by 
one-way analysis of variance (ANOVA) (Kruskal-Wallis test), P = 0.0007. (D) Distribution 
of neutrophils [polymorphonuclear leukocytes (PMNs)], monocytes, and B cells in 
the peripheral blood of WT and LPL−/− mice challenged with pneumococcus. Mice 
had received neonatal rGM-CSF therapy (GM) or PBS (P; control). (E) Number of 
AMs recovered from BAL fluid of WT or LPL−/− adult mice that survived 2 weeks 
after intratracheal pneumococcal infection. Grossly bloody BAL fluids were ex-
cluded from analysis (clotted). (F) Distribution of DCs, eosinophils, neutrophils 
(PMNs), and monocytes in whole-lung homogenates from uninfected adult WT 
and LPL−/− mice that had received neonatal rGM-CSF therapy or PBS (control). 
Percentages of total CD45+ cells are given. (C to F) Data are combined from three 
(C to E) or two (F) independent experiments. n of each group is given below 
x axes. P values of comparisons between two groups are determined using the 
Mann-Whitney U test.
24 hours after infection (blood culture)SurvivalB C
A
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administered systemic GM-CSF (26, 33). Our work shows that 
the route and timing of GM-CSF administration—directly to the 
airways, in the first 24 hours of life, to mimic the physiological 
burst of GM-CSF production that naturally occurs (9)—could 
exert effects very different from those previously observed when 
GM-CSF was administered systemically and, later, postnatally. 
In addition, the present studies expand on our prior work re-
vealing that LPL is an essential regulator of AM development 
(22, 25); we now show that beyond supporting the migration 
and adhesion of AMs and AM precursors into the alveoli (22), 
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Fig. 3. rGM-CSF administration increased pre-AM proliferation in LPL−/− pups. (A) Representative flow cytometry of BrdU incorporation into AMs and precursors 
(monocytes and pre-AMs, defined as shown) in whole-lung homogenates from PND3 WT and LPL−/− pups receiving rGM-CSF therapy or PBS (control). Percentage of cells 
in each gate incorporating BrdU listed in the top right-hand corner. (B) Quantification of the percentage of monocytes, pre-AMs, or AMs incorporating BrdU in PND3 WT 
or LPL−/− pups receiving neonatal rGM-CSF therapy (gray symbols) or PBS (control; open symbols). Each symbol represents one animal. Data are combined from three 
independent experiments. Line shows median value. P values are determined using the Mann-Whitney U test. (C) TGF- concentration in whole-lung homogenates from 
PND3 WT and LPL−/− pups receiving neonatal rGM-CSF therapy (gray bars) or PBS (open bars). Line shows the median value. n of each group is listed below the x axis. Data 
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Fig. 4. Neonatal rGM-CSF corrects increased SP-D in LPL−/− mice. (A) SP-D or (B) SP-A concentrations in whole-lung homogenates obtained from PND3 pups or adult 
WT or LPL−/− mice that had received neonatal rGM-CSF therapy (gray bars) or PBS (control; open bars). Line shows the median value. P values are determined using the 
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The observation that tissue-resident, long-lived macrophages arise 
during prenatal development and then self-renew (8) overturned 
the long-standing presumption that tissue-resident macrophages 
are continually repopulated from circulating blood monocytes. 
This finding prompted new work demonstrating the different 
ontogeny and function of varied macrophage lineages (9, 11, 14–18, 21). 
AMs represent a unique phagocytic lineage with a limited temporal 
window for development (9), occurring in the perinatal period and 
driven by a “burst” of GM-CSF occurring shortly after birth. The 
maturation pathway from fetal liver monocyte to mature AM has 
been well documented in mice (9, 14), and several key regulators 
have been identified (29). Translation to humans, which requires 
mapping of ontology and functional phenotypes of the multiple 
interstitial and AMs in mice to corresponding lineages in humans, 
will inform the role of each lineage in both lung infection and chronic 
lung disease (CLD) in preterm infants. One major obstacle to 
clinical translation has recently been overcome, as markers for clear 
differentiation of human AMs from interstitial lung macro-
phages have recently been defined (24, 33). The recent characteriza-
tion of distinct lineages (34, 35) now enables the re-evaluation of 
prior links between CLD outcome and lung macrophages; for 
instance, the macrophages studied in a landmark paper examining 
alveolarization inhibition by macrophage-specific pro-inflammatory 
signaling (5) were, in retrospect, likely fetal interstitial lung macro-
phages rather than AMs. The pathogenesis of CLD (including inhi-
bition of airway maturation) might be greatly clarified by additional 
studies leveraging new knowledge of macrophage lineages and AM 
development.
Existing clinical data, examined in light of the new murine para-
digm, support the consideration of AM maturation as a therapeutic 
target. First, a similar monocyte-to-AM maturation may occur in 
human infants (3, 6). While preterm lungs have been shown to bear 
monocytes (6), very few, if any, mature AMs are present in the lungs 
of stillborn infants (3, 24), strongly suggesting that AMs are not 
present in the lungs of infants in utero. In a cohort of live-born 
infants who died in the early neonatal period, AMs were present 
in 33 of 46 (72%) infants who died before 48 hours of age but were 
apparent in the lungs of 50 of 54 (93%) infants who survived longer 
than 48 hours (3). Thus, the emergence of AMs in the lungs of 
neonates correlated with time since birth, consistent with the murine 
model in which AM precursors differentiate to mature AM shortly 
after birth.
Moreover, the developmentally regulated increase of GM-CSF 
noted in newborn mice has also been observed in humans (23). An 
analysis of GM-CSF concentrations in amniotic fluid revealed gradually 
increasing GM-CSF concentrations, beginning at 28 weeks of gestation 
(23). After birth, tracheal aspirates demonstrated a sharp and significant 
increase in GM-CSF concentrations in samples between 12 and 
48 hours of age, after which concentrations did not change appreciably 
(23). This study provides evidence that GM-CSF may also increase 
at the time of birth in human infants, concurrently with the appearance 
of mature AMs.
Because AMs are phenotypically and functionally distinct from 
the interstitial macrophage lineages, delayed or disturbed AM 
maturation in preterm and term neonates could be pathophysiologically 
linked to either impaired immunity or increased pro-inflammatory 
signaling associated with bronchopulmonary dysplasia or CLD. For 
instance, the analysis of BAL fluid from preterm infants revealed 
a significant increase in nonclassical, pro-inflammatory CD14+/
CD16+ monocyte-macrophages and a decrease in the anticipated 
mature, anti-inflammatory CD14+/CD36+ macrophages compared 
to term infants. Furthermore, preterm infants that developed CLD 
had significantly fewer mature anti-inflammatory CD14+/CD36+ 
macrophages (AMs) recovered from BAL fluid than did preterm 
infants who did not develop CLD. Results from this study thus 
correlate with mouse ontogeny models, in that a higher proportion 
of immature (monocytic) cells is observed in preterm infants, and 
suggest that this perturbation is associated with CLD (6).
Our data support the concept that the augmentation of AM 
number and function, if perturbed in preterm infants, could confer 
translational benefit to the preterm lung, both by protecting against 
pulmonary infection (a common complication of prematurity) and 
by promoting surfactant function and metabolism [as reduced AM 
number impairs surfactant catabolism (36–38)]. In our mouse model 
of deficient AM maturation, intranasal rGM-CSF restored AM numbers 
and provided durable protection against pneumococcal challenge. 
Similarly, in preterm rabbits, reduced AM number correlated with 
increased susceptibility to group B streptococcal (GBS) lung infection 
(4). Specifically, preterm rabbits harbored barely detectable AMs and 
permitted the proliferation of GBS in the lungs, while term rabbits 
had 17-fold higher numbers of AMs than preterms and easily cleared 
a similar pulmonary GBS challenge (4). We also show an increase in 
SP-D concentrations in LPL−/− neonatal pups (Fig. 4A), consistent 
with reduced surfactant catabolism that would be anticipated with 
diminished numbers of AMs [Fig. 1B and (22)]. Exogenous neonatal 
rGM-CSF therapy reduced SP-D concentrations in PND3 LPL−/− pup 
lungs concordant with the acceleration in AM maturation, suggesting 
that the airway administration of GM-CSF to augment AM maturation 
may promote surfactant homeostasis in preterm neonates.
Our data show that administering three doses of intranasal GM-
CSF to neonatal mice is feasible and was effective in promoting AM 
maturation and pneumococcal clearance. The airway administration 
of GM-CSF has not been previously studied in clinical trials of 
human infants (26). One major clinical trial of GM-CSF administered 
subcutaneous (systemic) GM-CSF to preterm infants within 72 hours 
of birth, with a primary end point of sepsis-free survival at 14 days 
of life and with a goal of increasing peripheral neutrophil counts. 
No survival benefit of systemic GM-CSF was observed in this study 
nor were any differences in oxygen requirements observed at 28 days 
from enrollment (26). Follow-up evaluations of 2- and 5-year outcomes 
revealed no differences in neurodevelopmental, growth, or infectious 
outcomes with systemic GM-CSF administration (39, 40). We found 
that the subcutaneous administration of GM-CSF did not increase 
AM maturation as did direct airway administration (fig. S1). We 
propose that direct airway administration results in higher alveolar 
concentrations of rGM-CSF than does systemic injection, as systemic 
injection would distribute rGM-CSF throughout all tissues, while 
direct airway administration would provide a high alveolar concentration 
before systemic absorption. Further pharmacokinetic studies could 
define optimal dosing and timing of neonatal rGM-CSF to modify 
AM development. A meta-analysis revealed a higher response rate 
and greater improvements in PaO2 in subjects with autoimmune 
pulmonary alveolar proteinosis treated with inhaled GM-CSF than 
with subcutaneous GM-CSF (41). Inhaled GM-CSF has recently 
been used to successfully treat Mycobacterium abscessus infections 
in two patients with cystic fibrosis (42). We further note that we did 
not find any evidence of adverse effects of neonatal rGM-CSF airway 
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expected to be proceeding normally, as assessed by alveolarization, 
surfactant protein concentrations, and infectious susceptibility. We 
therefore suggest that revisiting GM-CSF therapy in neonates via 
this alternate route of administration would be warranted.
Furthermore, administering rGM-CSF to neonates with perturbed 
AM development produced a longer-lasting effect (8 to 12 weeks) 
than prior techniques using GM-CSF to protect against lung infections 
(43). For instance, adenoviral-mediated expression continuously 
delivered GM-CSF to the airway and protected mice from pneumococcal 
pneumonia 14 days later, but the effect of GM-CSF on leukocyte 
recruitment waned after 28 days of administration (43). The airway 
administration of GM-CSF also improved clearance of pneumococcus 
when given to adult mice from 12 hours before 6 hours after infection, 
but clinical translation of this application was limited by the narrow 
window of time for effective GM-CSF administration in relation to 
pneumococcal infection (43). The airway overexpression of GM-CSF 
driven by a surfactant promoter was also protective in a model of 
influenza infection, as was the administration of GM-CSF 1 week 
before infection (44). However, the sustained expression of GM-
CSF by either adenoviral or transgenic expression is not clinically 
translatable, and the effect of GM-CSF administered to adults was 
not durable. Our approach of administering GM-CSF during the 
neonatal window of AM development is therefore unique and 
clinically adaptable. We note that we did not challenge WT mice 
with a pneumococcal inoculum anticipated to induce notable 
mortality, as our intention was to test whether neonatal rGM-CSF 
therapy of LPL−/− mice rescued susceptibility (Fig. 2A). While we 
can conclude that neonatal rGM-CSF therapy did not increase 
susceptibility of WT animals to lung pneumococcal infection, further 
studies at higher inocula are required to test whether neonatal 
rGM-CSF therapy also boosts antipneumococcal immunity in WT 
mice. Last, also supporting the translatability of this approach, GM-
CSF has been administered to the airways of a small cohort of adults 
with refractory acute respiratory distress syndrome, providing 
benefit in oxygenation and lung compliance compared with control 
patients (45). The successful use of rGM-CSF to provide sustained 
protection against bacterial pneumonia in susceptible neonatal 
mice, without perturbing airway immunity and lung development 
in the normal host, illuminates how the airway administration of 
GM-CSF might be used in preterm infants to improve clinical 




The primary objective of this research was to test the hypothesis that 
administering rGM-CSF to neonatal LPL−/− pups (in the temporal 
window of AM development) would protect LPL−/− mice during 
subsequent bacterial lung infection. This objective was defined 
before initiation of the experiments and data analysis.
Experimental design
The experimental design was a controlled laboratory experiment 
using genetically modified mice.
Randomization
Pups within each litter of mice were randomly assigned to receive 
intranasal rGM-CSF or PBS (control). In one set of experiments, 
pups within litters were randomized to receive subcutaneous rGM-
CSF or PBS (control).
Blinding
Histology sections were read by a veterinary pathologist who was 
not associated with the study outcomes and was blinded to mouse 
genotype and treatment group (slides were provided with coded 
labels). Because of the technical challenges associated with working 
with timed pregnancies and neonatal pups, and the necessity of 
ensuring that pups receiving PBS could be consistently distinguished 
from the pups receiving rGM-CSF (pups were marked with permanent 
ink, but this would wear off if not reapplied), most of the studies 
could not be blinded. However, the outcomes are all objectively 
quantifiable [flow cytometry, colony forming units (CFU), etc.].
Mice
LPL−/− mice fully back-crossed to the C57BL/6 background have 
been described (22, 25). WT and LPL−/− mice were bred and cohoused 
in the same specific pathogen–free barrier animal facility. Human 
rGM-CSF (20 ng in 6 l of PBS per inoculation) was administered 
intranasally to pups in all experiments except for the data presented 
in fig. S1. In fig. S1, some neonatal pups received 20 ng of rGM-CSF 
in 10 l of PBS via subcutaneous injection. Litters of WT and LPL−/− 
pups were divided such that approximately half received PBS and 
half received rGM-CSF and such that littermate controls were used 
to discern the effects of rGM-CSF. Mice matched for sex and age 
were used in all experiments, which were conducted in accord-
ance with a protocol approved by the Institutional Animal Care 
and Use Committee at Washington University School of Medicine 
(WUSM).
Cell isolation and media
BAL was performed as described (25), and cells were quantified by 
flow cytometry (22). Lungs were homogenized using collagenase D 
(2.5 mg/ml) in Hanks’ balanced salt solution and 3% fetal calf serum 
(22).
Flow cytometry
Commercial antibodies to the indicated murine antigens were used: 
CD11c-phycoerythrin (PE)/Cy7, CD11c-allophycocyanin (APC) 
(N418), CD11c-APCCy7 (N418), CD64-PE (X54-5/7.1), F4/80-PerCP/
Cy5.5, F4/80-APC (BM8), I-Ak-PE (10-3.6), Ly-6C-PacBlue (HK1.4), 
Ly-6C-BV510 (HK1.4), CD45-PacBlue (30-F11), CD45-BV785 (30-F11), 
and Ly-6G-PacBlue (1A8) (all from BioLegend San Diego, CA); 
CD11b-fluorescein isothiocyanate (M1/70), CD11b-PeCy7 (M1/70), 
and CD11c-PE (N418) (all from eBioscience, San Diego, CA); CD45-
BV510 (104), SiglecF-PE, SiglecF–Alexa Fluor 647, SiglecF-APC700, 
and (E50-2440) Ly6G-BUV395 (1A8) (all from BD Biosciences, San 
Jose, CA); and MerTK-PE/Cy7 (DS5MMER) (from Invitrogen, 
Carlsbad, CA). BrdU labeling was performed using the BrdU-APC 
labeling Kit (BD Biosciences) according to the manufacturer’s 
protocol. Cells were acquired either on the BD Biosciences LSRFortessa 
or with a BD FACScan flow cytometer with DxP multicolor upgrades 
by Cytek Development Inc. (Woodland Park, NJ) and then analyzed 
using FlowJo software (FlowJo LLC, Ashland, OR). Samples were 
preincubated with Fc-block [Hybridoma 2.4G2, American Type 
Culture Collection (ATCC)].
Infection
Streptococcus pneumoniae [ATCC 6303, serotype 3; 5 × 104 CFU 
per animal in 20 l of Dulbecco’s PBS) was instilled intratracheally as 











Todd et al., Sci. Adv. 2019; 5 : eaax3387     14 August 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
8 of 9
after inoculation. Mice were monitored at least twice daily using a 
“humane end points” scoring system that included daily weight and 
temperature monitoring and observation of animals’ grooming, 
activity, behavior, and respirations. Animals that lost >20% of starting 
weight or that scored >5 on the clinical observation score were 
euthanized.
Tissues were harvested for either flow cytometry or for histology. 
Histological specimens were preserved in formalin (10%) and then 
embedded in paraffin. Sections were prepared and stained with 
hematoxylin and eosin by the Division of Comparative Medicine core 
facility at WUSM. Histological sections were reviewed by an independent 
veterinary pathologist.
Surfactant protein analysis
Concentrations of SP-A (Biotang Inc.) and SP-D (R&D Systems) in 
whole-lung homogenates were determined by enzyme-linked immuno-
sorbent assay according to the manufacturer’s protocol.
Statistics
Nonparametric tests were used to compare non-Gaussian data. All 
quantitative data are fully displayed in graphs, as they are represented 
either with box and whisker plots (line shows the median value, box 
shows 25th to 75th percentiles, and whiskers show minimum and 
maximum values) or with symbols indicating each value. Comparisons 
of two groups were made with the Mann-Whitney U test, and 
comparisons of multiple groups used the Kruskal-Wallis test. 
Survival curves were compared using the log-rank Mantel-Cox test. 
A P value of <0.05 was considered statistically significant.
As these studies were performed to generate preliminary data and 
demonstrate feasibility, power calculations could not be performed 
in advance; the number of experiments to be performed was deter-
mined on the basis of the number of experiments required in prior 
reports to demonstrate differences between groups of animals (22, 25). 
End points of all experiments were determined in advance of 
performing the experiment. All results of all experiments that were 
technically interpretable were included. No outliers from any ex-
periment were excluded. The number of animals and replicates for 
each experiment is provided in the figure or legend.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/8/eaax3387/DC1
Fig. S1. No increase in mature AMs following the subcutaneous administration of rGM-CSF 
(20 ng) to LPL−/− neonatal pups on DOB, PND1, and PND2.
Fig. S2. No disruption of alveolarization observed after intranasal neonatal rGM-CSF therapy.
Fig. S3. Increased SP-D in LPL−/− PND3 neonatal pups.
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